GNAQ and BRAF mutations show differential activation of the mTOR pathway in human transformed cells

PeerJ

Volumn 2013, Issue 1, 2013, Pages

  Pópulo, Helena ^a   Tavares, Sandra ^a   Faustino, Alexandra ^a   Nunes, Joana B ^a,b   Lopes, José Manuel ^a,b,c   Soares, Paula ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

^c HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

BRAF; GNAQ; MAPK; Melanoma; mTOR

Indexed keywords

1, 4 DIAMINO 1, 4 BIS (2 AMINOPHENYLTHIO) 2, 3 DICYANOBUTADIENE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; B RAF KINASE; BROXURIDINE; EVEROLIMUS; GUANINE NUCLEOTIDE BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SULFORHODAMINE B; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; NICK END LABELING; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSIENT TRANSFECTION; UVEA MELANOMA; WESTERN BLOTTING;

EID: 84885166168     PISSN: None     EISSN: 21678359     Source Type: Journal    
DOI: 10.7717/peerj.104     Document Type: Article

References (35)

1. Chang AE, Karnell LH, Menck HR. 1998. The National Cancer Data Base report on cutaneous and noncutaneous melanoma. Cancer 83:1664-1678 DOI 10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G.
2. Chen PW, Murray TG, Uno T, Salgaller ML, Reddy R, Ksander BR. 1997. Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease. Clinical and Experimental Metastasis 15:509-518 DOI 10.1023/A:1018479011340.
3. Clark GJ, Cox AD, Graham SM, Der CJ. 1995. Biological assays for Ras transformation. Methods in Enzymology 255:395-412 DOI 10.1016/S0076-6879(95)55042-9.
4. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, MellinghoffIK, Sawyers CL. 2008. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Medicine 5(1):e8 DOI 10.1371/journal.pmed.0050008.
5. Dahl C, Guldberg P. 2007. The genome and epigenome of malignant melanoma. APMIS 115:1161-1176 DOI 10.1111/j.1600-0463.2007.apm 855.xml.x.
6. Damato B. 2004. Developments in the management of uveal melanoma. Clinical and Experimental Ophthalmology 32:639-647 DOI 10.1111/j.1442-9071.2004.00917.x.
7. DeWaard-Siebinga I, BlomDJ, Griffioen M, Schrier PI, Hoogendoorn E, Beverstock G, Danen EH, Jager MJ. 1995. Establishment and characterization of an uveal-melanoma cell line. International Journal of Cancer 62:155-161 DOI 10.1002/ijc.2910620208.
8. Didolkar MS, Elias EG, Barber NA, Moore RH. 1980. Biologic behavior of ocular malignant melanoma and comparison with melanoma of the head and neck. American Journal of Surgery 140:522-526 DOI 10.1016/0002-9610(80)90204-4.
9. Faustino A, Couto JP, Populo H, Rocha AS, Pardal F, Cameselle-Teijeiro JM, Lopes JM, Sobrinho-Simoes M, Soares P. 2012. mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. Journal of Clinical Endocrinology Metabolism 97:E1139-1149 DOI 10.1210/jc.2011-2748.
10. Garcia-Marcos M, Ghosh P, Farquhar MG. 2011. Molecular basis of a novel oncogenic mutation in GNAO1. Oncogene 30:2691-2696 DOI 10.1038/onc.2010.645.
11. Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, Davies MA. 2010. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Research 70:8736-8747 DOI 10.1158/0008-5472.CAN-10-0902.
12. Gray-Schopfer V, Wellbrock C, Marais R. 2007. Melanoma biology and new targeted therapy. Nature 445:851-857 DOI 10.1038/nature05661.
13. Gray-Schopfer VC, Cheong SC, Chong H, Chow J, Moss T, Abdel-Malek ZA, Marais R, Wynford-Thomas D, Bennett DC. 2006. Cellular senescence in naevi and immortalisation in melanoma: a role for p16? British Journal of Cancer 95:496-505 DOI 10.1038/sj.bjc.6603283.
14. Ho AL, Musi E, Ambrosini G, Nair JS, Deraje Vasudeva S, de Stanchina E, Schwartz GK. 2012. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. PLoS ONE 7:e40439 DOI 10.1371/journal.pone.0040439.
15. Houben R, Vetter-Kauczok CS, Ortmann S, Rapp UR, Broecker EB, Becker JC. 2008. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. Journal of Investigative Dermatology 128:2003-2012 DOI 10.1038/jid.2008.30.
16. Khalili JS, Yu X, Wang J, Hayes BC, Davies MA, Lizee G, Esmaeli B, Woodman SE. 2012. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clinical Cancer Research 18:4345-4355 DOI 10.1158/1078-0432.CCR-11-3227.
17. Ksander BR, Rubsamen PE, Olsen KR, Cousins SW, Streilein JW. 1991. Studies of tumor-infiltrating lymphocytes from a human choroidal melanoma. Investigative Ophthalmology & Visual Science 32:3198-3208.
18. Kurmasheva RT, Huang S, Houghton PJ. 2006. Predicted mechanisms of resistance to mTOR inhibitors. British Journal of Cancer 95:955-960 DOI 10.1038/sj.bjc.6603353.
19. Lasithiotakis KG, Sinnberg TW, Schittek B, Flaherty KT, Kulms D, Maczey E, Garbe C, Meier FE. 2008. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. Journal of Investigative Dermatology 128:2013-2023 DOI 10.1038/jid.2008.44.
20. Luyten GP, Naus NC, Mooy CM, Hagemeijer A, Kan-Mitchell J, Van Drunen E, Vuzevski V, De Jong PT, Luider TM. 1996. Establishment and characterization of primary and metastatic uveal melanoma cell lines. International Journal of Cancer 66:380-387 DOI 10.1002/(SICI)1097-0215(19960503)66:3<380::AID-IJC19>3.0.CO;2-F.
21. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS. 2005. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436:720-724 DOI 10.1038/nature03890.
22. Miller AJ, Mihm MC Jr. 2006. Melanoma. The New England Journal of Medicine 355:51-65 DOI 10.1056/NEJMra052166.
23. Molhoek KR, Brautigan DL, SlingluffCL Jr. 2005. Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. Journal of Translational Medicine 3:39 DOI 10.1186/1479-5876-3-39.
24. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N. 2006. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Research 66:1500-1508 DOI 10.1158/0008-5472.CAN-05-2925.
25. O'Reilly T, McSheehy PM. 2010. Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): processes, limitations, and further proposals. Translational Oncology 3:65-79.
26. Populo H, Soares P, Faustino A, Rocha AS, Silva P, Azevedo F, Lopes JM. 2011a. mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics. Pigment Cell Melanoma Research 24:254-257 DOI 10.1111/j.1755-148X.2010.00796.x.
27. Populo H, Soares P, Rocha AS, Silva P, Lopes JM. 2010. Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma. Melanoma Research 20:107-117 DOI 10.1097/CMR.0b013e32832ccd09.
28. Populo H, Vinagre J, Lopes JM, Soares P. 2011b. Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas. British Journal of Ophthalmology 95:715-719 DOI 10.1136/bjo.2009.174417.
29. Reifenberger J, Knobbe CB, Sterzinger AA, Blaschke B, Schulte KW, Ruzicka T, Reifenberger G. 2004. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. International Journal of Cancer 109:377-384 DOI 10.1002/ijc.11722.
30. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. 1990. New colorimetric cytotoxicity assay for anticancer-drug screening. Journal of the National Cancer Institute 82:1107-1112 DOI 10.1093/jnci/82.13.1107.
31. Smalley KS, Herlyn M. 2004. Loitering with intent: new evidence for the role of BRAF mutations in the proliferation of melanocytic lesions. Journal of Investigative Dermatology 123:xvi-xvii DOI 10.1111/j.0022-202X.2004.23430.x.
32. Tarhini AA, Agarwala SS. 2006. Cutaneous melanoma: available therapy for metastatic disease. Dermatologic Therapy 19:19-25 DOI 10.1111/j.1529-8019.2005.00052.x.
33. Tolleson WH. 2005. Human melanocyte biology, toxicology, and pathology. Journal of Environmental Science and Health. Part C, Environmental Carcinogenesis & Ecotoxicology Reviews 23:105-161 DOI 10.1080/10590500500234970.
34. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, Simpson EM, Barsh GS, Bastian BC. 2009. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457:599-602 DOI 10.1038/nature07586.
35. Wolchok JD, Saenger YM. 2007. Current topics in melanoma. Current Opinion in Oncology 19:116-120 DOI 10.1097/CCO.0b013e32801497c6.